Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Berger

Showing results (1101-1110 of 1,161) with videos related to

Pageof 117
Sort By:
Genome Medicine|June 1, 2021
Tumor fraction-guided cell-free DNA profiling in metastatic solid tumor patientsDana W Y Tsui, Michael L Cheng, Maha Shady, et al.
JCO Precision Oncology|July 12, 2021
Prevalence and Characterization of Biallelic and Monoallelic <i>NTHL1</i> and <i>MSH3</i> Variant Carriers From a Pan-Cancer Patient PopulationErin E Salo-Mullen, Anna Maio, Semanti Mukherjee, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 4, 2019
Cancer Susceptibility Mutations in Patients With Urothelial MalignanciesMaria I Carlo, Vignesh Ravichandran, Preethi Srinavasan, et al.
Cancer Discovery|June 5, 2017
A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion-Positive Solid TumorsAlexander Drilon, Ramamoorthy Nagasubramanian, James F Blake, et al.
Cancer Discovery|December 24, 2021
Cancer-Causative Mutations Occurring in Early EmbryogenesisFresia Pareja, Ryan N Ptashkin, David N Brown, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|April 27, 2022
Germline Pathogenic Variants Impact Clinicopathology of Advanced Lung CancerSemanti Mukherjee, Chaitanya Bandlamudi, Matthew D Hellmann, et al.
JCO Precision Oncology|May 1, 2024
Natural History and Genomic Landscape of Chemotherapy-Resistant Muscle-Invasive Bladder CancerAndrew T Lenis, Karissa Whiting, Vignesh Ravichandran, et al.
Nature Medicine|November 27, 2019
Activating mutations in CSF1R and additional receptor tyrosine kinases in histiocytic neoplasmsBenjamin H Durham, Estibaliz Lopez Rodrigo, Jennifer Picarsic, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 11, 2017
AKT Inhibition in Solid Tumors With AKT1 MutationsDavid M Hyman, Lillian M Smyth, Mark T A Donoghue, et al.
Cancer Discovery|March 25, 2017
Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging TherapiesEmmet J Jordan, Hyunjae R Kim, Maria E Arcila, et al.
Pageof 117

Showing results (1101-1110 of 1,161) with videos related to

Sort By:
Pageof 117
Genome Medicine|June 1, 2021
Tumor fraction-guided cell-free DNA profiling in metastatic solid tumor patientsDana W Y Tsui, Michael L Cheng, Maha Shady, et al.
JCO Precision Oncology|July 12, 2021
Prevalence and Characterization of Biallelic and Monoallelic <i>NTHL1</i> and <i>MSH3</i> Variant Carriers From a Pan-Cancer Patient PopulationErin E Salo-Mullen, Anna Maio, Semanti Mukherjee, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 4, 2019
Cancer Susceptibility Mutations in Patients With Urothelial MalignanciesMaria I Carlo, Vignesh Ravichandran, Preethi Srinavasan, et al.
Cancer Discovery|June 5, 2017
A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion-Positive Solid TumorsAlexander Drilon, Ramamoorthy Nagasubramanian, James F Blake, et al.
Cancer Discovery|December 24, 2021
Cancer-Causative Mutations Occurring in Early EmbryogenesisFresia Pareja, Ryan N Ptashkin, David N Brown, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|April 27, 2022
Germline Pathogenic Variants Impact Clinicopathology of Advanced Lung CancerSemanti Mukherjee, Chaitanya Bandlamudi, Matthew D Hellmann, et al.
JCO Precision Oncology|May 1, 2024
Natural History and Genomic Landscape of Chemotherapy-Resistant Muscle-Invasive Bladder CancerAndrew T Lenis, Karissa Whiting, Vignesh Ravichandran, et al.
Nature Medicine|November 27, 2019
Activating mutations in CSF1R and additional receptor tyrosine kinases in histiocytic neoplasmsBenjamin H Durham, Estibaliz Lopez Rodrigo, Jennifer Picarsic, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 11, 2017
AKT Inhibition in Solid Tumors With AKT1 MutationsDavid M Hyman, Lillian M Smyth, Mark T A Donoghue, et al.
Cancer Discovery|March 25, 2017
Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging TherapiesEmmet J Jordan, Hyunjae R Kim, Maria E Arcila, et al.
Pageof 117